companies / varmx-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-08 json
| total_raised | 2,700,0002.7M | ○ |
|---|---|---|
| founded | 2010 | |
| hq | Leiden, Netherlands | |
| industry | unknown | |
| stage | null |
VarmX develops VMX-C001, a universal reversal agent that restores blood coagulation in patients on Factor Xa direct oral anticoagulants. It serves emergency-medicine teams treating severe bleeding and surgeons operating on anticoagulated patients. Its mechanism-agnostic restoration of clotting works across all FXa-DOACs, where the only approved competitor (Andexxa) targets only apixaban and rivaroxaban.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-06-01 | grant | 2,700,0002.7M | null | ○ |
Cloudflare, reCAPTCHA, Google Analytics, Google Tag Manager, Font Awesome, jQuery CDN, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, Elementor 4.0.9, DoubleClick Floodlight, Cloudflare Bot Management, Contact Form 7 6.1.6
| fact | status | src |
|---|---|---|
| Grant, $2.7M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |